These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 28593442)
1. Remodeling of heterochromatin structure slows neuropathological progression and prolongs survival in an animal model of Huntington's disease. Lee J; Hwang YJ; Kim Y; Lee MY; Hyeon SJ; Lee S; Kim DH; Jang SJ; Im H; Min SJ; Choo H; Pae AN; Kim DJ; Cho KS; Kowall NW; Ryu H Acta Neuropathol; 2017 Nov; 134(5):729-748. PubMed ID: 28593442 [TBL] [Abstract][Full Text] [Related]
2. Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington's disease mouse model. Hwang YJ; Hyeon SJ; Kim Y; Lim S; Lee MY; Kim J; Londhe AM; Gotina L; Kim Y; Pae AN; Cho YS; Seong J; Seo H; Kim YK; Choo H; Ryu H; Min SJ J Enzyme Inhib Med Chem; 2021 Dec; 36(1):856-868. PubMed ID: 33771089 [TBL] [Abstract][Full Text] [Related]
3. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Ryu H; Lee J; Hagerty SW; Soh BY; McAlpin SE; Cormier KA; Smith KM; Ferrante RJ Proc Natl Acad Sci U S A; 2006 Dec; 103(50):19176-81. PubMed ID: 17142323 [TBL] [Abstract][Full Text] [Related]
4. In silico probing and biological evaluation of SETDB1/ESET-targeted novel compounds that reduce tri-methylated histone H3K9 (H3K9me3) level. Park I; Hwang YJ; Kim T; Viswanath ANI; Londhe AM; Jung SY; Sim KM; Min SJ; Lee JE; Seong J; Kim YK; No KT; Ryu H; Pae AN J Comput Aided Mol Des; 2017 Oct; 31(10):877-889. PubMed ID: 28879500 [TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca(2+) signaling in Huntington's disease. Lee J; Hwang YJ; Shin JY; Lee WC; Wie J; Kim KY; Lee MY; Hwang D; Ratan RR; Pae AN; Kowall NW; So I; Kim JI; Ryu H Acta Neuropathol; 2013 May; 125(5):727-39. PubMed ID: 23455440 [TBL] [Abstract][Full Text] [Related]
6. Mechanism suppressing H3K9 trimethylation in pluripotent stem cells and its demise by polyQ-expanded huntingtin mutations. Irmak D; Fatima A; Gutiérrez-Garcia R; Rinschen MM; Wagle P; Altmüller J; Arrigoni L; Hummel B; Klein C; Frese CK; Sawarkar R; Rada-Iglesias A; Vilchez D Hum Mol Genet; 2018 Dec; 27(23):4117-4134. PubMed ID: 30452683 [TBL] [Abstract][Full Text] [Related]
7. Epigenetics of Huntington's Disease. Bassi S; Tripathi T; Monziani A; Di Leva F; Biagioli M Adv Exp Med Biol; 2017; 978():277-299. PubMed ID: 28523552 [TBL] [Abstract][Full Text] [Related]
8. ATRX induction by mutant huntingtin via Cdx2 modulates heterochromatin condensation and pathology in Huntington's disease. Lee J; Hong YK; Jeon GS; Hwang YJ; Kim KY; Seong KH; Jung MK; Picketts DJ; Kowall NW; Cho KS; Ryu H Cell Death Differ; 2012 Jul; 19(7):1109-16. PubMed ID: 22240898 [TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. Ferrante RJ; Ryu H; Kubilus JK; D'Mello S; Sugars KL; Lee J; Lu P; Smith K; Browne S; Beal MF; Kristal BS; Stavrovskaya IG; Hewett S; Rubinsztein DC; Langley B; Ratan RR J Neurosci; 2004 Nov; 24(46):10335-42. PubMed ID: 15548647 [TBL] [Abstract][Full Text] [Related]
11. ESET methylates UBF at K232/254 and regulates nucleolar heterochromatin plasticity and rDNA transcription. Hwang YJ; Han D; Kim KY; Min SJ; Kowall NW; Yang L; Lee J; Kim Y; Ryu H Nucleic Acids Res; 2014 Feb; 42(3):1628-43. PubMed ID: 24234436 [TBL] [Abstract][Full Text] [Related]